Arcellx, Inc.

Bristol Myers Squibb is moving to take over its longtime cell therapy partner 2seventy bio and the CAR-T cell therapy they developed and commercialized together, Abecma (idecabtagene vicleucel). The b

The data that Gilead Sciences subsidiary Kite and Arcellx presented at the American Society of Hematology meeting for anitocabtagene autoleucel (anito-cel) were positive, but the question that remains

The current leader in the multiple myeloma CAR-T market, Legend and J&J ’s Carvykti, looks to have a serious challenger in the shape of Arcellx / Gilead ’s anitocabtagene autoleucel (anito-cel

Gilead Sciences’ COVID-19 drug Veklury (remdesivir) saw some rare year-over-year sales growth while the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) saw an even rarer decline in sales in the